Dyax Corp. (NASDAQ:DYAX) CMO Burt A. Adelman sold 55,000 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $9.68, for a total transaction of $532,400.00. Following the transaction, the chief marketing officer now directly owns 37,500 shares in the company, valued at approximately $363,000. Dyax Corp. (NASDAQ:DYAX) shares after opening at $9.38 moved to $9.38 on last trade day and at the end of the day closed at $8.88. Company price to sales ratio in past twelve months was calculated as 19.70 and price to cash ratio as 9.53.Dyax Corp. (NASDAQ:DYAX) showed a negative weekly performance of -3.79%.
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, reported its financial results and business update for the fourth quarter and the year ended December 31, 2013. Synergy is developing plecanatide for the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C). Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares fell -1.62% in last trading session and ended the day on $6.08. SGYP return on equity ratio is recorded as -112.90% and its return on assets is -89.00%. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) yearly performance is 6.48%.
The story begins with Aastrom Biosciences Inc (NASDAQ:ASTM)having gained significantly in the previous session, just as it has become normal of it in recent times. Shares rose 25.19 percent to $4.97. Although the current market price of the stock is still a far cry from its one-year high of $24.40, it is encouraging to note that a lot of positive things have been happening around the stock and it could just be a matter of time before a complete turnaround is achieved. But talk is cheap, so they say, that is why apart from the rhetoric, it is important to plunge into the facts and figures to reveal Aastrom for what it is currently and what it is shaping up to be in the future. Aastrom Biosciences Inc (NASDAQ:ASTM) shares moved up 30.58% in last trading session and was closed at $6.49, while trading in range of $5.15-$7.00. Aastrom Biosciences Inc (NASDAQ:ASTM) year to date performance is 100.93%.
A number of analysts have recently weighed in on MDXG shares. Analysts at Northland Capital Partners downgraded shares of MiMedx Group from an “outperform” rating to a “market perform” rating in a research note on Monday, January 6th. They now have a $6.00 price target on the stock. On the ratings front, analysts at Northland Securities downgraded shares of MiMedx Group from an “outperform” rating to a “market perform” rating in a research note on Monday, January 6th. They noted that the move was a valuation call. MiMedx Group Inc (NASDAQ:MDXG) weekly performance is -15.16%. On last trading day company shares ended up $6.21. MiMedx Group Inc (NASDAQ:MDXG) distance from 50-day simple moving average is -16.84%. Analysts mean target price for the company is $9.25.